West Pharmaceutical Services(NYSE) WST

West Pharmaceutical Services makes the packaging and tools used to inject medicines safely into patients. It helps drug companies store and deliver treatments for conditions like diabetes and cancer. These products ensure medicines stay clean and work correctly when a doctor or patient uses them.

Vials, Stoppers, and Self-Injection Tools

• Proprietary Products: Injectable packaging like rubber stoppers, seals, and plastic vials; accounted for 82% of net sales in 2025.
• Self-Injection Systems: Wearable and handheld devices that let patients give themselves medicine at home; included in the Proprietary Products segment.
• Contract Manufacturing: Design and assembly of complex medical devices for other companies; accounted for 18% of net sales in 2025.
• Integrated Solutions: Laboratory testing and technical support to help drug companies meet safety rules for their packaging.

Strategic Moves and Partnerships

• Developed the SmartDose 3.5mL On-Body Delivery System and recently agreed to sell the manufacturing rights to AbbVie.
• Maintains a long-term licensing agreement with Daikyo Seiko, Ltd. to use specialized coating and plastic technologies like Crystal Zenith.
• Expanded manufacturing capacity at multiple global sites during 2025 to meet the growing demand for injectable drug components.

What Makes West Stand Out?

The company operates a global network with manufacturing sites across North America, Europe, and Asia to serve the world's largest drug makers. It holds specialized knowledge in how medicines react with packaging, which helps prevent contamination and ensures drug stability.

The Scorecard: Financial Facts

• Net sales reached $805 million in Q4 2025, a 7.5% increase from Q4 2024.
• Free cash flow rose to $175 million in Q4 2025, up 105.4% from $85 million in the same period a year ago.
• Gross profit for Q4 2025 was $303.9 million, an increase of 10.8% year-over-year.
• Operating income for Q4 2025 was $156.6 million, down 8.2% from the $170.6 million reported in Q4 2024.
• International sales were a significant driver of performance, representing 56.7% of total net sales during 2025.

Bottom Line

West has transitioned from a component manufacturer into a provider of integrated delivery systems for the biologics and generics markets. Its focus on high-value proprietary technology supports its role in the global supply chain for injectable medicines.